A plant for the production of intravenous nutrition will appear in the Technopolis Moscow SEZ

0
mos.ru

Pharmaceutical production of parenteral nutrition will open at the Alabushevo site of the Technopolis Moscow Special Economic Zone (SEZ). Gennady Degtev, General Director of the Moscow SEZ, and Inga Nizharadze, General Director of the Skopinsky Pharmaceutical Plant, signed the agreement at the St. Petersburg International Economic Forum (SPIEF-2025).

The investment project to establish a high-tech production complex for therapeutic parenteral nutrition products will generate over 180 jobs.

The agreement provides for cooperation on technical and commercial issues. Additionally, the Moscow Special Economic Zone (SEZ) and the Skopinsky Pharmaceutical Plant agreed to collaborate on developing international relations. This includes organizing foreign business trips for specialists and delegations, as well as exchanging data on potential Russian and foreign partners.

Inga Nizharadze, the general director of the Skopinsky Pharmaceutical Plant, noted that the company’s task is to introduce a new, high-quality domestic product to the Russian market of essential drugs. Cooperation with Technopolis Moscow SEZ and OOO Skopinfarm will make it possible to effectively implement this project.

Fourteen companies are forming a pharmaceutical cluster at the Moscow SEZ. Eight of these enterprises have already begun production and are receiving a variety of tax incentives. Half of the pharmaceutical companies have localized their production at the largest Special Economic Zone (SEZ) site, Alabushevo.

Earlier, the Moscow City Hall reported that Acrus BioMed, a resident company of the Technopolis Moscow Special Economic Zone (SEZ), became Russia’s first company in Russia to produce samples of high-tech cell therapies for clinical trials. There are currently trials of three therapies that involve engineering a patient’s own cells for the treatment of spinal cord injuries, joint damage, and critical burns.

НЕТ КОММЕНТАРИЕВ

WordPress Ads
Exit mobile version